Nogra Pharma Limited is a private pharmaceutical development company founded in 2005 and based in Dublin, Ireland. The company has already has one successful product on the market for the treatment of ulcerative colitis, sold under the names Lialda in the US and Mezavant in Europe and elsewhere and which is marketed in partnership with Shire.

Nogra specialises in the early stage development of products targeted at the gastro-intestinal area, and particularly aimed at relieving inflammatory symptoms of auto-immune reactions. Nogra is very pleased with the results to date from trials of its second product which is focused on the treatment of Crohn's disease, and is delighted to have found a strong partner in Celgene to drive forward the continued trial and development of its product towards a successful launch on the market.